March 29 (Reuters) – An advisory panel to the U.S. Food and Drug Administration recommended an approval for Acadia Pharmaceuticals Inc’s drug for psychosis related to Parkinson’s disease.
The post FDA panel backs Acadia drug for psychosis linked to Parkinson’s appeared first on NASDAQ.